Understanding the role of APP proteins in Alzheimer's disease
Official title: Structural characterization of APP family proteins
Funded at Rutgers Biomedical and Health Sciences · NIH-10815785 · Data updated 2026-11-12
This study is looking at a protein called APP to understand how it contributes to Alzheimer's disease, with the hope of finding new ways to help improve brain health for people living with this condition.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $157,000 |
| NIH project number | 5R03AG081787-02 |
| Project ID | NIH-10815785 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk for developing the condition.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's disease may not receive benefit from this research.
What this research studies
This research investigates the amyloid precursor protein (APP) and its involvement in Alzheimer's disease (AD), a condition that leads to progressive cognitive decline. The study aims to characterize the structural properties of APP proteins to better understand their role in the formation of amyloid plaques and the overall pathology of AD. By examining how APP functions in neuronal development and synaptic activity, the research seeks to uncover potential therapeutic targets for improving brain health in individuals affected by Alzheimer's. Patients may benefit from insights gained into APP's role in AD progression and potential new treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for Alzheimer's disease, potentially improving cognitive function and quality of life for patients.
How similar studies have gone: Previous research has shown promising results in targeting APP and its pathways, indicating that this approach could lead to significant advancements in Alzheimer's treatment.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Petrou, Vasileios I — Rutgers Biomedical and Health Sciences
- Study coordinator: Petrou, Vasileios I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.